ATE343392T1 - Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom - Google Patents

Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom

Info

Publication number
ATE343392T1
ATE343392T1 AT01983031T AT01983031T ATE343392T1 AT E343392 T1 ATE343392 T1 AT E343392T1 AT 01983031 T AT01983031 T AT 01983031T AT 01983031 T AT01983031 T AT 01983031T AT E343392 T1 ATE343392 T1 AT E343392T1
Authority
AT
Austria
Prior art keywords
metabolic syndrome
risk factors
factors associated
reduce risk
lactobacillus strain
Prior art date
Application number
AT01983031T
Other languages
English (en)
Inventor
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Application granted granted Critical
Publication of ATE343392T1 publication Critical patent/ATE343392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01983031T 2000-11-10 2001-11-12 Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom ATE343392T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004124A SE0004124D0 (sv) 2000-11-10 2000-11-10 New use

Publications (1)

Publication Number Publication Date
ATE343392T1 true ATE343392T1 (de) 2006-11-15

Family

ID=20281779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983031T ATE343392T1 (de) 2000-11-10 2001-11-12 Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom

Country Status (16)

Country Link
US (1) US20040048356A1 (de)
EP (1) EP1331938B1 (de)
JP (1) JP4200518B2 (de)
KR (2) KR100886728B1 (de)
CN (1) CN1226039C (de)
AT (1) ATE343392T1 (de)
AU (2) AU1448602A (de)
CA (1) CA2434035C (de)
DE (1) DE60124131T2 (de)
DK (1) DK1331938T3 (de)
ES (1) ES2269480T3 (de)
NO (1) NO330992B1 (de)
NZ (1) NZ525657A (de)
PL (1) PL203824B1 (de)
SE (1) SE0004124D0 (de)
WO (1) WO2002038165A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010075495A (ko) * 1998-10-01 2001-08-09 추후보정 산화성 스트레스 인자의 감소
CN1293186C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1313600C (zh) * 2002-10-30 2007-05-02 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293185C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293187C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
SE527555C2 (sv) 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
DK3067057T3 (da) 2005-09-28 2023-02-13 Nordic Rebalance As Probiotisk fermenteret cerealiesammensætninger til anvendelse ved behandling af gastrointestinale lidelser forårsaget af pro-inflammatoriske bakterier
RU2008134892A (ru) * 2006-01-27 2010-03-10 Даниско А/С (Dk) Применение пробиотичеких микроорганизмов для лечения и профилактики ожирения и связанных с ним расстройств
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
JP5201832B2 (ja) * 2006-12-25 2013-06-05 花王株式会社 脂肪分解促進用皮膚外用剤
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
EP2011506A1 (de) 2007-07-05 2009-01-07 Nestec S.A. Ergänzung zu einer Schwangerschaftsdiät
KR101010914B1 (ko) * 2008-04-28 2011-01-26 주식회사 엔유씨전자 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄
US20120020944A1 (en) 2009-03-25 2012-01-26 Chr-Hansen A/S Use of a probiotic to regulate body weight
US20120107291A1 (en) 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
MX348112B (es) 2009-12-22 2017-05-26 Probi Ab Composiciones no fermentadas que comprenden una fracción a base de cereal y un probiótico y usos de estos.
KR101426276B1 (ko) * 2012-08-16 2014-08-05 주식회사한국야쿠르트 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
KR101470995B1 (ko) * 2013-08-30 2014-12-09 주식회사 바이오리쏘스 프로피온산 생산능을 갖는 미생물 및 그를 포함하는 조사료 조성물
KR101500974B1 (ko) * 2014-08-22 2015-03-13 (주) 에이투젠 항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도
CN105105145B (zh) * 2015-09-14 2022-04-22 吉林省命之元生物科技有限公司 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用
GB201519327D0 (en) 2015-11-02 2015-12-16 Optibiotix Health Ltd Composition
CN105567601A (zh) * 2016-01-29 2016-05-11 江苏绿科生物技术有限公司 一种植物乳杆菌及其应用
CA3046705A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
WO2018216735A1 (ja) * 2017-05-26 2018-11-29 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善又は治療用組成物
KR102063772B1 (ko) * 2019-07-23 2020-01-08 주식회사 메디오젠 혈당 강하 효과 및 항산화 효과를 갖는 유산균
CN112126604B (zh) * 2020-09-30 2022-05-17 江南大学 一株可降低高血压发生风险因子的植物乳杆菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient

Also Published As

Publication number Publication date
ES2269480T3 (es) 2007-04-01
CA2434035C (en) 2011-06-07
KR20040018304A (ko) 2004-03-03
DE60124131D1 (de) 2006-12-07
CA2434035A1 (en) 2002-05-16
DE60124131T2 (de) 2007-03-29
NO330992B1 (no) 2011-09-05
NZ525657A (en) 2005-05-27
AU1448602A (en) 2002-05-21
US20040048356A1 (en) 2004-03-11
JP2004520276A (ja) 2004-07-08
WO2002038165A1 (en) 2002-05-16
CN1486189A (zh) 2004-03-31
NO20032056L (no) 2003-05-08
PL203824B1 (pl) 2009-11-30
CN1226039C (zh) 2005-11-09
AU2002214486B2 (en) 2007-04-26
SE0004124D0 (sv) 2000-11-10
JP4200518B2 (ja) 2008-12-24
EP1331938A1 (de) 2003-08-06
PL362221A1 (en) 2004-10-18
NO20032056D0 (no) 2003-05-08
EP1331938B1 (de) 2006-10-25
KR100886728B1 (ko) 2009-03-04
DK1331938T3 (da) 2007-02-12
KR20080047628A (ko) 2008-05-29

Similar Documents

Publication Publication Date Title
ATE343392T1 (de) Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom
WO2006044556A3 (en) Dual inhibitors of lipoxygenase for treating diabetes
Gao et al. Meta‐analysis and critical review on the efficacy and safety of alpha‐glucosidase inhibitors in Asian and non‐Asian populations
MX2007000406A (es) Solucion para infusion e inyeccion de levodopa.
AP1763A (en) Pulmonary administration of chemically modified insulin
BRPI0608271A2 (pt) controle superior de glicose no sangue em tratamento de diabette
de Winter-de Groot et al. Nitric oxide in cystic fibrosis
EP1500403A4 (de) Mittel zur prävention/behandlung von diabetes
WO2008043033A3 (en) Fibrillation-resistant insulin and insulin analogues
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
Sanz et al. Purification and characterization of an aminopeptidase from Lactobacillus sake
WO2005049792A3 (en) Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
NZ608292A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
HK1143066A1 (en) Ranolazine for elevated brain-type natriuretic peptide
WO2007015132A3 (en) Use of specific lactic bacteria for the preparation of immunomodulating compositions
Olivares et al. The Janus Face of Cereals: Wheat‐Derived Prebiotics Counteract the Detrimental Effect of Gluten on Metabolic Homeostasis in Mice Fed a High‐Fat/High‐Sucrose Diet
Roessler et al. Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease
WO2003013559A1 (fr) Absorbant/adsorbant d'acide biliaire
Chen et al. Mechanism and application of Lactobacillus in type 2 diabetes-associated periodontitis
Tavintharan et al. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells
WO2000047721A3 (en) Methods of inducing insulin positive progenitor cells
WO2008011179A3 (en) Omega-3 fatty acids for use in treating resistant hypertension
WO2004060135A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2006007710A3 (en) Acute inflammatory condition treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1331938

Country of ref document: EP